Lupin launches Doxorubicin Hydrochloride Liposome Injection in US, ET HealthWorld

Mumbai: Lupin Limited announced the launch of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials in the US after Lupin’s alliance partner, ForDoz Pharma Corporation, US, received approval for its ANDA from the United States Food and Drug Administration (US FDA).

Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials is a generic equivalent of Doxil (Liposomal), of Baxter Healthcare Corporation, indicated for the treatment of ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi’s Sarcoma, and multiple myeloma.

Doxorubicin Hydrochloride Liposome Injection (RLD Doxil (Liposomal)) had an estimated annual sales of $40.9 million in the US (IQVIA MAT June 2024).